Amelioration of Experimental Autoimmune Encephalomyelitis by the Quinoline-3-Carboxamide Paquinimod

The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects

“…Further, paquinimod did not reduce the number of steady state CD11b + peritoneal cells. We also have previously reported that paquinimod treatment does not influence the production of myeloid cells in the bone marrow [41]. Third, the reduced cell number in the paquinimod-treated mice could be caused by increased efflux of recruited cells, i.e.…”

“…Taken together, these data provide important implications for the understanding of the beneficial effects of Q-compounds observed both in autoimmune disease [30,40,41] and cancer [61,62]. Both autoimmune diseases and the growth of solid tumors involve inflammation mediated by myeloid cells.…”

“…In that model we could show that the CD115 + subpopulation of the inflammatory monocytes was selectively reduced in treated mice [41]. We therefore wanted to investigate whether paquinimod treatment would reduce this particular sub-population also in the current model of subcutaneous inflammation, and we found that this was indeed the case ( Figure 3A).…”

“…Recently, the S100A9 protein was identified as one molecular target of the Q-compound paquinimod (ABR-215757) [40]. We have previously shown that paquinimod interferes with development of disease both in mouse models of multiple sclerosis [40,41] and systemic lupus erythematosus [42]. Further, our previous work indicated that this compound interfered with the accumulation of myeloid cells during inflammation [43].…”

Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis

“…Paquinimod has immunomodulatory properties and interferes with development of disease in models for several autoimmune/inflammatory disorders, e.g. multiple sclerosis (MS) [11], systemic lupus erythematosus (SLE) [12] and atherosclerosis [13]. The immunomodulatory effects of paquinimod in these models involve the innate immune system, specifically the myeloid cell compartment and it was recently reported that paquinimod selectively inhibited recruitment of subsets of myeloid cells into inflammatory sites [14].…”